Abstract
In neuroblastoma, the most frequent genetic alterations are unbalanced translocations involving chromosome 17. To gain insights into these rearrangements, we have characterized a previously identified der(1)t(1;17) of the CLB-Bar cell line. The 17q breakpoint was mapped by FISH. Subsequently, a rearranged fragment was identified by Southern analysis, cloned in a lambda vector and sequenced. The chromosome rearrangement is more complex than expected due to the presence of an interstitial 4p telomeric sequence between chromosome 1p and 17q. Three different genes, which may play a role in neuroblastoma development, are disrupted by the translocation breakpoints. Indeed, the 3′UTR of the PIP5K2B gene on chromosome 17q is directly fused to the (TTAGGG)n repeat of the chromosome 4p telomere, and the (1;4) fusion disrupts the MACF1 (microtubule-actin crosslinking factor 1) and POLN genes, respectively. Interestingly, the (1;4) fusion was present at diagnosis and at relapse, whereas the (4;17) fusion was detected at relapse only, leading to a secondary 17q gain confirmed by array CGH therefore indicating that 17q gain may not be a primary event in neuroblastoma. Finally, screening of a panel of neuroblastoma cell lines identified interstitial telomeric sequences in three other cases, suggesting that this may be a recurrent mechanism leading to unbalanced translocations in neuroblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bown N . (2001). J. Clin. Pathol., 54, 897–910.
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G and Speleman F . (1999). N. Engl. J. Med., 340, 1954–1961.
Brodeur GM . (2003). Nat. Rev. Cancer, 3, 203–216.
Caron H, van Sluis P, van Roy N, de Kraker J, Speleman F, Voute PA, Westerveld A, Slater R and Versteeg R . (1994). Am. J. Hum. Genet., 55, 341–347.
Castellino AM, Parker GJ, Boronenkov IV, Anderson RA and Chao MV . (1997). J. Biol. Chem., 272, 5861–5870.
Christiansen H, Franke F, Bartram CR, Adolph S, Rudolph B, Harbott J, Reiter A and Lampert F . (1987). Cancer Genet. Cytogenet., 26, 235–244.
Di Paolo G, Pellegrini L, Letinic K, Cestra G, Zoncu R, Voronov S, Chang S, Guo J, Wenk MR and De Camilli P . (2002). Nature, 420, 85–89.
Gong TW, Besirli CG and Lomax MI . (2001). Mammary Genome, 12, 852–861.
Greaves MF and Wiemels J . (2003). Nat. Rev. Cancer, 3, 639–649.
Lastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson AD and Jackson MS . (2002). Genes Chromosomes Cancer, 34, 428–436.
Lastowska M, Cullinane C, Varind S, Cotterill S, Bown N, O'Niell S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson ADJ and Jackson M . (2001). J. Clin. Oncol., 19, 3080–3090.
Marini F, Kim N, Schuffert A and Wood RD . (2003). J. Biol. Chem., 278, 32014–32019.
Meddeb M, Danglot G, Chudoba I, Venuat AM, Benard J, Avet-Loiseau H, Vasseur B, Le Paslier D, Terrier-Lacombe MJ, Hartmann O and Bernheim A . (1996). Genes Chromosomes Cancer, 17, 156–165.
Perri P, Longo L, Cusano R, McConville CM, Rees SA, Devoto M, Conte M, Ferrara GB, Seri M, Romeo G and Tonini GP . (2002). Oncogene, 21, 8356–8360.
Roberts T, Chernova O and Cowell JK . (1998). Hum. Mol. Genet., 7, 1169–1178.
Sambrook J and Russel D . (2000). Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York.
Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A and Delattre O . (2003). Cancer Genet. Cytogenet., 141, 32–42.
Schleiermacher G, Raynal V, Janoueix-Lerosey I, Combaret V, Aurias A and Delattre O . (2004). Genes Chromosomes Cancer, 39, 143–150.
Sossey-Alaoui K, Su G, Malaj E, Roe B and Cowell JK . (2002). Oncogene, 21, 5967–5974.
Spitz R, Hero B, Ernestus K and Berthold F . (2003). Clin. Cancer Res., 9, 4835–4840.
Trakhtenbrot L, Cohen N, Betts DR, Niggli FK, Amariglio N, Brok-Simoni F, Rechavi G and Meitar D . (2002). Cancer Genet. Cytogenet., 137, 95–101.
Van Roy N, Vandesompele J, Berx G, Staes K, Van Gele M, De Smet E, De Paepe A, Laureys G, van der Drift P, Versteeg R, Van Roy F and Speleman F . (2002). Genes Chromosomes Cancer, 35, 113–120.
Yamazaki M, Miyazaki H, Watanabe H, Sasaki T, Maehama T, Frohman MA and Kanaho Y . (2002). J. Biol. Chem., 277, 17226–17230.
Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH and de Lange T . (2003). Mol. Cell, 12, 1489–1498.
Acknowledgements
GS is a recipient of a grant from the Academie Nationale de Medecine. This work was supported by grants from the Ligue Nationale Contre le Cancer (Equipe labellisée). The construction of the 3.3k BAC array was supported by grants from the Carte d'Identité des Tumeurs (CIT) Program of the Ligue Nationale Contre Le Cancer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schleiermacher, G., Bourdeaut, F., Combaret, V. et al. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene 24, 3377–3384 (2005). https://doi.org/10.1038/sj.onc.1208486
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208486
Keywords
This article is cited by
-
Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate
BMC Cancer (2021)
-
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
Journal of Experimental & Clinical Cancer Research (2020)
-
Molecular pathogenesis of peripheral neuroblastic tumors
Oncogene (2010)
-
Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data
Oncogene (2007)
-
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
British Journal of Cancer (2007)